Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency

Author： Bernstein Jonathan A   Biedenkapp Joseph  

Publisher： Future Science

ISSN： 2041-6792

Source： Clinical Investigation, Vol.3, Iss.9, 2013-09, pp. : 859-873

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of on‐demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency

By  

ALLERGY, Vol. 70, Iss. 12, 2015-12 ,pp. : 1553-1558

John Wiley & Sons Inc

Access to resources Recommend Favorite

Overview of ecallantide in the treatment of hereditary angioedema types I and II

By Banta Erin   Craig Timothy J  

Therapy, Vol. 7, Iss. 5, 2010-09 ,pp. : 565-571

Future Medicine

Access to resources Recommend Favorite

Hereditary Angioedema: Long-Term Treatment with One or More Injections of C1 Inhibitor Concentrate per Week

By  

International Archives of Allergy and Immunology, Vol. 154, Iss. 1, 2010-07 ,pp. : 81-88

Karger

Access to resources Recommend Favorite

Long-Term Prophylaxis of Hereditary Angioedema with a Pasteurized C1 Inhibitor Concentrate

By  

International Archives of Allergy and Immunology, Vol. 154, Iss. 4, 2010-10 ,pp. : 356-359

Karger

Access to resources Recommend Favorite

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate

By  

ALLERGY, Vol. 105-4538, Iss. 10, 2015-10 ,pp. : 1319-1328

John Wiley & Sons Inc

Access to resources Recommend Favorite